Moderna CFO exercises 2,475 RSUs, shares withheld

Q: What insider transaction did Moderna (MRNA) disclose for its CFO on September 1, 2026?

Moderna disclosed that CFO James M. Mock had 2,475 restricted stock units convert into 2,475 shares of common stock on September 1, 2026, as part of a scheduled vesting of his equity compensation.

Q: How many Moderna (MRNA) shares were withheld for taxes in this Form 4?

In connection with the RSU vesting, 1,197 shares of Moderna common stock were withheld at $140.34 per share to satisfy tax withholding obligations related to James M. Mock’s vested restricted stock units.

Q: What is the conversion rate of Moderna (MRNA) restricted stock units in this filing?

The filing states that Moderna’s restricted stock units convert into common stock on a one-for-one basis, meaning each vested RSU delivers one share of Moderna common stock.

Q: What vesting schedule applies to the reported Moderna (MRNA) restricted stock units?

For this award, 25% of the RSUs vested on March 1, 2026, with the remaining 75% vesting in twelve equal quarterly installments after that date, as disclosed in the footnotes.

Moderna’s CFO reported RSU vesting into common stock, with a portion of shares withheld to cover tax obligations.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Moderna, Inc. (MRNA) reported that Chief Financial Officer James M. Mock exercised restricted stock units on September 1, 2026, converting 2,475 restricted stock units into an equal number of shares of common stock on a one-for-one basis. In connection with this vesting, 1,197 common shares were withheld at a price of $140.34 per share to satisfy tax withholding obligations. Following this transaction, Mr. Mock continued to hold 24,755 restricted stock units subject to the award, which vested 25% on March 1, 2026, with the remainder vesting in twelve equal quarterly installments thereafter. No Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

2,475 shares exercised/converted

Exercise 3 txns

Insider Mock James M

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units ^{F1, F3}	2,475	$0.00	$0.00
Exercise	Common Stock ^F1	2,475	--	--
Tax Withholding	Common Stock ^F2	1,197	$140.34	$168K

Holdings After Transaction: Restricted Stock Units — 24,755 contracts (Direct); Common Stock — 68,282 shares (Direct)

Footnotes (3)

F1. Restricted stock units convert into common stock on a one-for-one basis.
F2. Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3. 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Key Figures

Restricted stock units converted: 2,475 units Common shares acquired from RSU conversion: 2,475 shares Shares withheld for tax obligations: 1,197 shares +4 more

7 metrics

Restricted stock units converted 2,475 units RSUs converted into common stock on September 1, 2026

Common shares acquired from RSU conversion 2,475 shares Shares of Moderna common stock received by the CFO

Shares withheld for tax obligations 1,197 shares Common shares withheld upon RSU vesting on September 1, 2026

Tax withholding price per share $140.34 per share Price used for shares withheld to satisfy tax withholding obligations

Restricted stock units remaining under award 24,755 units RSUs reported as held after the September 1, 2026 conversion

Initial vesting portion 25% Portion of RSU award that vested on March 1, 2026

Remaining vesting schedule installments 12 quarterly installments Schedule for the remaining RSUs after initial 25% vest

Key Terms

Restricted Stock Units, tax withholding obligations, Rule 10b5-1 trading plan

3 terms

Restricted Stock Units financial

"Restricted stock units convert into common stock on a one-for-one basis"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares withheld at the election of the Reporting Person to satisfy tax withholding obligations"

Rule 10b5-1 trading plan regulatory

"No Rule 10b5-1 trading plan is reported for these transactions"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

What insider transaction did Moderna (MRNA) disclose for its CFO on September 1, 2026?

Moderna disclosed that CFO James M. Mock had 2,475 restricted stock units convert into 2,475 shares of common stock on September 1, 2026, as part of a scheduled vesting of his equity compensation.

How many Moderna (MRNA) shares were withheld for taxes in this Form 4?

In connection with the RSU vesting, 1,197 shares of Moderna common stock were withheld at $140.34 per share to satisfy tax withholding obligations related to James M. Mock’s vested restricted stock units.

What is the conversion rate of Moderna (MRNA) restricted stock units in this filing?

The filing states that Moderna’s restricted stock units convert into common stock on a one-for-one basis, meaning each vested RSU delivers one share of Moderna common stock.

What vesting schedule applies to the reported Moderna (MRNA) restricted stock units?

For this award, 25% of the RSUs vested on March 1, 2026, with the remaining 75% vesting in twelve equal quarterly installments after that date, as disclosed in the footnotes.

How many Moderna (MRNA) restricted stock units does the CFO continue to hold after this transaction?

After the September 1, 2026 conversion, James M. Mock is reported as holding 24,755 restricted stock units subject to this award, which continue to vest according to the stated quarterly schedule.

Was a Rule 10b5-1 trading plan used for the Moderna (MRNA) insider transactions?

No. The filing indicates that the Rule 10b5-1 checkbox is not marked, so no Rule 10b5-1 trading plan is reported in connection with these transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/03/2026 - 05:03 PM Accepted by SEC EDGAR 09/03/2026 - 04:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mock James M

(Last)

(First)

(Middle)

C/O MODERNA, INC.

325 BINNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/01/2026		M⁽¹⁾		2,475	A	⁽¹⁾	69,479	D
Common Stock	09/01/2026		F⁽²⁾		1,197	D	$140.34	68,282	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	09/01/2026		M⁽¹⁾			2,475	⁽³⁾	⁽³⁾	Common Stock	2,475	$0	24,755	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.

3. 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

	/s/ James Dillon, As Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR